Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Galapagos N.V. (NASDAQ: GLPG).

Full DD Report for GLPG

You must become a subscriber to view this report.


Recent News from (NASDAQ: GLPG)

JF's Core Biotech Buys #15: Removal Of A Key Overhang, Buying Weakness In I-O, Updates And Adding To 2 Positions
Welcome to the fifteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size ...
Source: SeekingAlpha
Date: May, 14 2018 11:37
JF's Core Biotech Buys #14: Introducing Our Final 2 Positions & Taking Advantage Of Weakness In The I-O Space
Welcome to the fourteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size...
Source: SeekingAlpha
Date: May, 07 2018 15:40
Institutional Top Ideas Series: Orbimed Advisors
In the last entry of this series, we took a look at top ideas from Baker Bros. Advisors (whose performance has been struggling of late but they've built up a stellar reputation and track record of long term outperformance). Going forward, I hope to continue to delve into the portfolios of...
Source: SeekingAlpha
Date: May, 04 2018 03:18
Gilead Denies It Stumbled: Is The Selling Overdone Or Just Starting?
Introduction - Gilead misses but keeps guidance Gilead ( GILD ) was a $20 stock in 2011 when it did the deal that brought it Sovaldi and enabled the rest of its HCV line of three combination products. In only 4 1/2 years, it was a $120 stock and has spent the next almost two years either d...
Source: SeekingAlpha
Date: May, 02 2018 08:29
Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atopic dermatitis patients
Mechelen, Belgium and Planegg/Munich, Germany; 1 May 2018; 22.01 CET - Galapagos NV (Euronext & NASDAQ: GLPG) and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that the first patient has been screened in IGUANA, a Phase 2 study with MOR106, an...
Source: GlobeNewswire
Date: May, 01 2018 16:02
JF's Core Biotech Buys #13: Continued Market Headwinds And How To Respond
Welcome to the thirteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size...
Source: SeekingAlpha
Date: May, 01 2018 02:41
Vertex Hits Stumbling Block For One Triple-Combo Therapy For Cystic Fibrosis
Recently, Vertex Pharmaceuticals ( VRTX ) announced an update on one of its programs dealing with a triple-combo treatment for cystic fibrosis. It was announced that a phase 3 triple-combo dealing with VX-561 would be put on hold on safety concerns . This is somewhat bad news for Vertex, ...
Source: SeekingAlpha
Date: April, 30 2018 07:17
Galapagos presents strong disease-modifying effects in preclinical model of osteoarthritis with GLPG1972 at OARSI 2018
Mechelen, Belgium; 27 April 2018, 7.30 CET - Galapagos NV (Euronext & NASDAQ: GLPG) presents preclinical results showing broad beneficial effects on cartilage and bone with GLPG1972 in an osteoarthritis (OA) rat model at the Osteoarthritis Research Society International (OARSI) World C...
Source: GlobeNewswire
Date: April, 27 2018 01:31
Galapagos 2018 Q1 - Results - Earnings Call Slides
The following slide deck was published by Galapagos in conjunction with their 2018 Q1 earnings Read more ...
Source: SeekingAlpha
Date: April, 26 2018 14:35
Galapagos' (GLPG) CEO Onno van de Stolpe on Q1 2018 Results - Earnings Call Transcript
Galapagos NV (GLPG) Q1 2018 Earnings Conference Call April 26, 2018 8:00 AM ET Executives Elizabeth Goodwin – Vice President-Investor Relations and Corporate Communications Onno van de Stolpe – Chief Executive Officer Bart Filius – Chief Operating Officer and...
Source: SeekingAlpha
Date: April, 26 2018 14:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1797.6396.6897.6396.2458,018
2017-02-0266.1767.8867.9766.11160,943
2017-02-0166.7067.2467.4066.3087,362
2017-01-3164.0165.1065.3463.69102,236
2017-01-3065.4264.3165.4663.7686,604

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1513,58227,33449.6890Short
2018-08-144,23510,09141.9681Short
2018-08-133,50614,97523.4124Cover
2018-08-104,6888,68753.9657Short
2018-08-095,83320,81028.0298Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on GLPG.


About Galapagos N.V. (NASDAQ: GLPG)

Logo for Galapagos N.V. (NASDAQ: GLPG)

Galapagos is a midsized biotechnology company, with therapeutic programs based on proprietary disease modifying drug targets, and a focus on inflammation, orphan disease, and anti infectives. Galapagos approach is to develop drugs that stop or reverse a disease state using novel targets that are identified through a patent protected target discovery platform. Galapagos also provides access to its target and drug discovery platform through its services division, BioFocus and Argenta, which offers a full suite of target to drug discovery products and services to pharmaceutical and biotech companies.

 

Contact Information

 

 

Current Management

  • Onno van de Stolpe / CEO
  • Guillaume Jetten / CFO
  • Elizabeth Goodwin / IR Manager
  • Raj Parekh / Chairman

Current Share Structure

  • Market Cap: $2,555,535,509 - 05/16/2018
  • Issue and Outstanding: 26,770,747 - 12/31/2012

 


Recent Filings from (NASDAQ: GLPG)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 02 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 01 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 27 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 25 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 24 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 16 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: March, 23 2018
Annual and transition report of foreign private issuers under sections 13 or 15(d)
Filing Type: 20-FFiling Source: edgar
Filing Date: March, 23 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: March, 21 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: March, 08 2018

 

 


Daily Technical Chart for (NASDAQ: GLPG)

Daily Technical Chart for (NASDAQ: GLPG)


Stay tuned for daily updates and more on (NASDAQ: GLPG)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: GLPG)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in GLPG is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of GLPG and does not buy, sell, or trade any shares of GLPG. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/